Ad
Friday, 29 September 2017
Roche's Perjeta regimen gets FDA priority review in breast cancer
ZURICH (Reuters) - The U.S. Food and Drug Administration (FDA) has granted priority review for Roche's Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment